ANNUAL REPORT
YEAR ENDING 30 JUNE 2022
BTC HEALTH LIMITED
www.btc hea lth.c om.a u
ASX:BTC
Contents
Chairman’s Letter
Directors' Report
Corporate Governance Statement
Financial Report
Directors' Declaration
Auditor's Independence Declaration
Independent Auditor's Report
Shareholder Information
Directory
2
4
11
17
38
39
40
43
45
BTC HEALTH | ANNUAL REPORT
PG 1
Chairman’s
Letter
Dear Shareholder,
We have continued to diversify our healthcare investments and the BTC health product portfolio currently
distributed by our investee companies spans both medical devices and speciality pharmaceuticals. Our investment
strategy is directed towards high-growth niches within the healthcare market, making novel technologies available
to patients and clinical staff, with the goal of supporting improved clinical outcomes and strong returns for
investors.
Sales to hospitals by our investee entities were $8.2m for the year ended 30 June 2022 (2021: $7.3m). Although full
year sales were below our internal target, reflecting ongoing constraints in general hospital operating conditions, it
was very pleasing nevertheless for the BTC health business to deliver top line sales growth of 12% over 2021.
Healthcare environment
The healthcare sector has navigated many challenges over the last year including fluctuating elective surgery rates,
a surge in winter respiratory illnesses, hospital staff shortages and deferral of non-urgent medical procedures.
Consequently, the number of patients waiting on elective surgery remains at an all-time high. BTC health’s investee
companies are well positioned to capitalise on the anticipated uplift in elective surgery rates, as well as a
normalisation of patient visits to asthma and cystic fibrosis respiratory clinics.
Integration of new investments
I am pleased to confirm the speciality respiratory pharmaceutical products acquired by our investee company,
BioImpact Pty Ltd, have been fully integrated and are being utilised by respiratory clinics across the country. Both
Bronchitol® and Aridol® address unmet healthcare needs of a niche patient population and BTC health is proud
to be able to make these products available, to support patients in ongoing disease management. Bronchitol® is
used as a second line mucociliary clearance drug for patients suffering from cystic fibrosis and without this
medication, lung clearance would prove challenging and patient mobility compromised. Aridol® is an innovative
lung function test designed to help doctors diagnose and manage asthma by detecting active airway
inflammation through measuring airway hyper-responsiveness. Sales of both products were $1.3m in financial
year 2022 and BTC’s investee companies anticipate ongoing minimum growth of 3% per annum. These
growth expectations are consistent with BTC health’s initial investment expectations.
BTC health seeks to further expand its investments in speciality pharmaceutical assets including orphan
drugs. Several opportunities are being actively considered by BioImpact Pty Ltd, which if concluded may allow
for these novel products to be made available to Australian patients under the Special Access Scheme (SAS), in
advance of BTC health making a full marketing application to the Therapeutic Goods Administration (TGA). We
are pleased to be using the strength and reach of our global network to identify and source novel drug
therapies, which whilst registered in other jurisdictions around the world, have yet to be made available to
patients in Australia and New Zealand.
BTC HEALTH | ANNUAL REPORT
PG 2
Government reforms
The Department of Health (DOH) is presently working through a series of healthcare funding reforms in relation to
the funding pathways for the Pharmaceutical Benefit Scheme (PBS) and the Prosthesis List (PL). These schemes
regulate the funding of pharmaceuticals and medical devices in Australia. A large proportion of sales from BTC
health’s investee companies are from products which are reimbursed either through the PBS or via the PL. Although
the commercial impact of these reforms has to date been relatively small, we anticipate further legislative changes
over the course of the next 12 months. In response, we are engaging actively with the DOH, our suppliers and
customers to ensure we maintain both product margins and patient access, and secondly that our in-licensing
strategy gives a relatively greater focus to products with reimbursement falling outside the scope of the PBS and PL
frameworks.
Community
BTC health, through its investee company BTC Speciality Health Pty Ltd, is proud to be a gold sponsor of Great Strides,
a major cystic fibrosis fundraising event held annually in Melbourne and Sydney during September. Funds raised
from Great Strides will be used to provide support services to people living with cystic fibrosis. As a small Australian
healthcare company BTC health is committed to investing in our community in ways that provide a meaningful and
positive impact.
Diversity
BTC health celebrates and values a diversified workforce. Our dynamic team of employees and contractors represent
different skills, backgrounds, and genders. The BTC health group (including investee companies) recruits the best
talent for each position and is proud to have a workforce that currently comprises 43% women. We believe that as
a high-growth company a source of competitive advantage is in our ability to critically evaluate different ideas,
whilst fostering an agile and engaging work environment that lives our shared company values.
Growth Strategy
Notwithstanding the widely acknowledged disruptions from the pandemic, BTC continued to invest significant time
and resources in the evaluation and due diligence of two significant potential transactions, one in the pharmaceutical
space and the other in medical equipment and consumables. Both targets were considered transformative
opportunities for BTC health’s investee companies, providing a clear pathway towards greater scale and profitability
for the combined business.
Despite the strong underlying rationale in each case, it is regrettable that these transactions did not proceed. In
the one instance, BTC health and the vendor were unable to agree on key terms central to the investment case.
And in the second instance, the recent state of capital markets, combined with certain constraints under the
Pooled Development Fund Act, presented an uncertain funding environment for the transaction, circumstances
which the BTC health board considered were not in shareholders’ best interests to proceed.
Once capital markets improve, transformative merger and acquisition targets will again be considered, however
in the present environment BTC health has chosen to focus its growth strategy on non-dilutive opportunities
including new agency distribution agreements. New agencies generally provide incremental revenue and
returns to BTC without the need for significant capital outlay. Through its investee companies, BTC health
has four agency opportunities under discussion, two for novel medical devices and two in respect of novel
speciality pharmaceuticals.
The Board would like to thank its employees, customers, shareholders, and supply partners for their ongoing
support over the last 12 months. As a high-growth Australian SME we continue to set high expectations for our
business as we create a path forward to achieve greater operating scale, sustainable profitability along with
improved liquidity and valuation of our issued share capital.
Dr. Richard S Treagus
Chairman
BTC HEALTH | ANNUAL REPORT
PG 3
Directors’
Report
The directors of BTC health Limited present their report on the audited financial statements of BTC health Limited for the
year ended 30 June 2022.
Directors
The following persons were directors of BTC health Limited (“the Company”) during the whole of the financial
year and up to the date of this report, unless stated otherwise:
-
-
-
Richard Spencer Treagus
Jonathan Charles Pilcher
Bruce Alwyn Hewett
Principal Activities
BTC health is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The Company
holds investments, and continues to actively seek investment opportunities, in entities operating in the healthcare sector.
Review of Operations and Results
Revenue from continuing operations for the year of $95,004 (2021: $19,190) largely comprised management fees of
$94,368 (2021: $13,333). Operating loss after income tax increased to $576,076 (2021: $391,686), primarily due to cost
of options issued $200,932 (2021: $nil) and partially offset by an increase in management fee income. Operating
costs increased to $671,080 (2020: $410,876) which includes the cost of options issued.
BTC health held active interests in two investment companies at 30 June 2022. The valuation of each investee company is
recognised on the balance sheet. During the year, BTC health converted loans to the investee companies of $2.6m to equity
within the investee companies. A movement in the fair value of BTC health’s investments is recognised in the Company’s
statement of profit and loss.
BTC Speciality Health Pty Ltd
BTC health’s wholly owned investee company BTC Speciality Health is an established distributor of medical devices and
consumables in the Australian and New Zealand healthcare markets. The company has been successful in executing its
growth plan, with sales to hospitals growing 12% to $8.2m for the financial year 30 June 2022 (2021: $7.3m). BTC Speciality
health is focused on continuing to grow and diversify its product portfolio to increase its product offering to the hospital
sector and speciality clinics, and in so doing, deliver incremental returns to its shareholder BTC health Limited. BTC health’s
equity investment in BTC Speciality Health increased to $7.9m (2021: $6.0m), due to the conversion of loans outstanding
from the investee company to equity at 30 June 2022
BioImpact Pty Ltd
BTC health’s wholly owned investee company BioImpact, licenses and holds intellectual property rights for healthcare
products. During the financial year, BioImpact acquired the sale and distribution rights to Bronchitol® and Aridol® from
Pharmaxis for $2.0m. These rights have been further sublicensed to BTC Speciality Health for the commercial distribution
and promotion to clinical staff and patients. BioImpact will continue to acquire the rights to innovative drug and device
BTC HEALTH | ANNUAL REPORT
PG 4
products from manufacturers around the world. BTC health values the equity investment in BioImpact Pty Ltd at
$2,883,975 (2021: $2,000,100). Loans outstanding from the investee company were converted to equity in the investee
company at 30 June 2022.
Financial Position
At 30 June 2022, the company’s net assets were $12,861,964 compared with $10,837,108 at 30 June 2021. Cash reserves
as at 30 June 2022 were $2,170,493, compared with $2,368,975 at 30 June 2021. The net tangible asset backing per share
as at 30 June 2022 equated to 4.56 cents (2021: 4.40 cents).
Dividends
No dividends have been declared in respect of the financial year ended 30 June 2022 (2021: nil).
Business Strategies and Future Prospects
BTC health has undertaken a strategic review of its investments to ensure assets are able to generate sufficient returns in
the medium term to shareholders. The Company is committed to supporting investee companies in the healthcare sector
given the favorable drivers of demand for patient care. The Company is consistently assessing a pipeline of assets to in-
license or acquire which align within its capabilities and growth strategy. This may include individual products or target
companies within the hospital or specialised medical care sectors. The company will advise shareholders when
additional capital is required for a material investment.
BTC health has supported investment in infrastructure to ensure its investee companies are well positioned to grow
organically and through licensing and distribution agreements. The primary objective for BTC Speciality Health is to increase
market share through organic growth and new product introductions. Whereas new medical devices, consumables and
speciality pharmaceutical products will continue to be sourced by BioImpact.
Information on Directors
Director
Experience
Special
Responsibilities
Particulars of Directors’ Interest
as at 16 August 2022
Shares
Options
24,613,207
6,000,000
Executive
Chairman
R S Treagus
BScMed, MBChB, MPharmMed, MBA,
MAICD. Dr Treagus is a physician and
entrepreneur with over 25 years’
experience in all aspects of the international
pharmaceutical and biotechnology industry.
Formerly a Director of Neuren
Pharmaceuticals Limited.
Appointed 4 August 2014. Age 56.
J C Pilcher
BSc, FCA. Mr Pilcher is a Chartered Accountant
and holds a degree in biotechnology from the
University of Reading in the UK. Currently the CEO
and Managing Director of Neuren
Pharmaceuticals Limited.
Non-
Executive
Director
Appointed 1 September 2015. Age 56.
B A Hewett
B of App Sc (Pharm) GAICD. Bruce graduated as
a pharmacist and has had over 30 years’
experience in all aspects of the pharmaceutical
industry.
Appointed 5 August 2019. Age 68.
Non-
Executive
Director
125,000
-
100,000
-
Company Secretary
Sharon Papworth has over 20 years’ finance experience, including over 10 years in the healthcare sector. She is a member
of Chartered Accountants Australia and New Zealand
BTC HEALTH | ANNUAL REPORT
PG 5
Remuneration Report (Audited)
This report outlines the remuneration arrangements in place for key management personnel of BTC health Limited -
(“Company”). As the company is an investment entity and the investee companies are not consolidated, the amounts
disclosed in the tables below exclude amounts paid by the investee companies. Amounts paid by the investee companies
are separately disclosed below.
The following persons acted as directors and were also the key management personnel of the company during the
financial year: Richard Spencer Treagus Jonathan Charles Pilcher Bruce Alwyn Hewett Sharon Papworth
Remuneration Policy
The performance of the company depends upon the quality of its directors and executives. To prosper, the company must
attract, motivate and retain highly skilled directors and executives. The fees for services provided by Directors have been
determined contractually and at arm’s length. The Board has not appointed a Remuneration Committee and this function
is being undertaken by the Board.
Bruce Hewett was paid a fixed non-executive director fee of $40,000 per annum, effective 1 October 2021 (previously fixed
at $20,000 per annum). Mr. Hewett received director fees of $35,000 for the financial year ended 30 June 2022. Jonathan
Pilcher was paid a fixed non-executive director and audit committee chairman fee of $60,000 per annum, effective 1
October 2021 (previously fixed at $40,000 per annum). Mr. Pilcher received director fees of $51,250 for the financial year
ended 30 June 2022.The director fees are determined by the board.
Richard Treagus is an executive director. Effective 1 October 2021, Dr. Treagus receives a director fee of $40,000 per annum
and an executive fee of $360,000 per annum, the latter is charged to BTC Speciality Health Pty Ltd. Previously Dr. Treagus
received a combined director and executive fee of $180,000 per annum. Executive director fees totaled $97,500 for the
financial year. The Company and BTC Speciality Health Pty Ltd have entered into service contracts with PharmaConnect Pty Ltd
(an entity associated with Richard Treagus) and each contract may be terminated by either party providing three month’s
written notice. Other than payments to PharmaConnect Pty Ltd for directors fees, there were no material transactions with
the company in the year (Note 16).
No Directors are entitled to long service leave or annual leave.
Company Performance and Link to Company Performance
Non-executive directors receive fixed rate remuneration, with no link to Company performance. The executive director may
receive a bonus for executive services provided to BTC Speciality Health Pty, where investee company objectives and financial
performance goals are achieved. There was no bonuses earned for the financial year ended 30 June 2022.
The following table shows the revenue, the operating result and net assets of the Company for the last 5 years as well as
the share price and earnings per share at the end of the respective financial years.
Revenue from continuing operations
Investment fair value adjustment
Net Profit/ (Loss) after tax
Dividend Paid
Share Placement
Net Assets
2017
2018
2019
2020
2021
2022
28,496
62,937
187,763
169,604
19,190
95,004
-
144,900
130,000
125,000
-
-
(516,527)
(1,467,834)
(692,742)
(283,036)
(391,686)
(576,076)
-
-
-
-
1,973,346
347,628
8,849,798
160,757
-
-
-
2,400,000
3,978,873
2,973,002
11,341,485
11,228,794
10,837,108 12,861,964
Share price at Year end (in cents)
Basic earnings per Share (in cents)
0.16
0.20
0.085
0.10
0.074
0.04
(0.45)
(1.14)
(0.51)
(0.12)
(0.16)
(0.20)
BTC HEALTH | ANNUAL REPORT
PG 6
Remuneration of Directors:
2022
SHORT TERM
EMPLOYEE
BENEFITS
POST-
EMPLOYMENT
BENEFITS
EQUITY
SETTLED
SHARES
OTHER LONG-
TERM
BENEFITS
$
$
$
Salary and Fees
Superannuation
97,500
-
133,955
46,591
4,659
35,000
-
-
-
R S Treagus
(Chairman)
J C Pilcher
(non-executive)
B Hewett
(non-executive)
Total Remuneration
179,091
4,659
133,955
$
-
-
-
-
2021
SHORT TERM
EMPLOYEE BENEFITS
POST-
EMPLOYMENT
BENEFITS
$
$
Salary and Fees
Superannuation
R S Treagus
(Chairman)
J C Pilcher
(non-executive)
B Hewett
(non-executive)
180,000
-
36,530
3,470
20,000
-
Total Remuneration
236,530
3,470
EQUITY
SETTLED
SHARES
OTHER LONG-
TERM BENEFITS
$
-
-
-
-
$
-
-
-
-
TOTAL
$
231,455
51,250
35,000
317,705
TOTAL
$
180,000
40,000
20,000
240,000
Equity Settled Shares
Other than Dr. Richard Treagus, no directors of the Company received any share-based payments as part of their
remuneration during the
financial year ended 30 June 2022 (2021: None). Dr. Richard Treagus was granted
6,000,000 share options, approved at the Annual General Meeting held on 23 November 2021. A total of 2,000,000
share options vested immediately and options expire 5 years from vesting date. The exercise price of the vested share
options is $0.12 each. The value of vested share options totaled $133,955. Remaining options will be granted in two
tranches, assuming service conditions are met. There were no other share based payments issued to directors during the
year ended 30 June 2022.
Remuneration by investee companies
In addition to the remuneration disclosed above, Dr. Richard Treagus received $270,000 for executive services (2021: $nil)
from BTC Speciality Health, where time is spent leading the investee entities growth strategy. The executive director may
receive a performance based bonus where investee company objectives and financial performance goals are achieved.
There was no bonus earned for the financial year ended 30 June 2022 (2021: $11,250).
BTC HEALTH | ANNUAL REPORT
PG 7
Directors Meetings
The number of meetings of the company’s board of directors (including committees of directors) held for the year ended
30 June 2022, and the number of meetings attended by each director were:
NUMBER OF
DIRECTOR
MEETINGS
NUMBER OF
DIRECTOR
MEETINGS
ATTENDED
NUMBER OF
AUDIT
COMMITTEE
MEETINGS
NUMBER OF
MEETINGS
ATTENDED
R S Treagus
J C Pilcher
B A Hewett
11
11
11
11
11
11
-
2
2
-
2
2
CFO & Company Secretary
Sharon Papworth was appointed CFO and Company Secretary on 1 October 2019. Remuneration is recorded in BTC health’s
investee company, BTC Speciality Health, where the majority of time is allocated. Sharon Papworth received $285,000 in
remuneration for the year ended 30 June 2022 (2021: $285,000), including post-employment benefits. Under the
Employee Share Option Plan, 2,000,000 share options were granted to the CFO and Company Secretary on 23 November
2021. A total of 666,666 share options vested immediately and options expire 5 years from vesting date. The exercise price
of the vested share options is $0.12 each. The value of vested share options totaled $44,652. Remaining options will be
granted in two tranches, assuming service conditions are met. The CFO and Company Secretary may receive a
performance based bonus where investee company objectives and financial performance goals are achieved. There was no
bonus earned for the financial year ended 30 June 2022 (2021: $13,200).
Remuneration Practices
No director appointed during the period received a payment as part of his or her consideration for agreeing to hold the
position. The remuneration of each director has been established on the basis of a flat fee, inclusive of any superannuation
benefit. Thus, there is no direct link between performance and the level of remuneration.
Share holdings
The numbers of shares in the Company held during the financial year by each director of BTC health Limited, including their
personally related entities, are set out below:
Year ended 30 June 2022
NAME
Ordinary shares
R S Treagus
J C Pilcher
B A Hewett
BALANCE AT
THE START OF
THE YEAR
ADDITIONS
EQUITY
SETTLED
SHARES
OTHER NET
CHANGES
DURING THE
YEAR
BALANCE AT THE
END OF THE YEAR
24,613,207
125,000
-
-
45,000
55,000
-
-
-
-
-
-
24,613,207
125,000
100,000
BTC HEALTH | ANNUAL REPORT
PG 8
Share option holdings
The terms and conditions of each grant of share options in the company held during the financial year by each director of
BTC health Limited, including their personally related entities, are set out below:
Year ended 30 June 2022
GRANT DATE
NUMBER OF
OPTIONS
GRANTED
VESTING
DATE AND
EXERCISABLE
DATE
EXPIRY
DATE
EXERCISE
PRICE
FAIR VALUE
PER OPTION
AT GRANT
DATE
NAME
Share options
R S Treagus
2,000,000
23.11.2021
23.11.2021
23.11.2026
R S Treagus
2,000,000
23.11.2021
23.11.2022
23.11.2027
R S Treagus
2,000,000
23.11.2021
23.11.2023
23.11.2028
$0.12
$0.12
$0.12
$0.038
$0.033
$0.030
There were no share options held at the start of the year, and no changes to share options other than as shown in the
table above. A total of 6,000,000 share options were held at the end of the year.
Transactions with directors and director related entities
The terms and conditions of transactions with directors and their related entities were no more favorable than those
available or which might reasonably be expected to be available, on similar transactions to non-director entities on an arm’s
length basis.
End of Remuneration Report
BTC HEALTH | ANNUAL REPORT
PG 9
Auditor Independence Declaration to the Directors
The directors have received the auditors’ independence declaration which is included on page 39 of this report.
Insurance of Directors and Officers
During the financial year, the Company paid a premium of $59,950 (2021: $59,550) including GST to insure the
directors and officers of the Company. The liabilities insured are costs and expenses that may be incurred in
defending civil or criminal proceedings that may be brought against the officers in their capacity as officers of the company
or a related body corporate.
Share Options
At the date of this report, BTC health Limited has 9,000,000 (2021: 5,000,000) unissued ordinary shares under option.
Under the Employee Share Option Plan, 9,000,000 share options were granted on 23 November 2021, a total 2,999,999 share
options vested immediately, options expire 5 years from vesting date. The exercise price of the vested share options is $0.12
each. The value of vested share options totaled $114,526. Remaining options will be granted in two tranches, assuming service
conditions are met.
Significant Events after the Balance Date
No matters or circumstances have arisen since the end of the financial year which significantly affected or may
significantly affect the operations of the company, the results of those operations or the state of affairs of the company in
future financial years.
Likely Developments and Expected Results of Operations
BTC health is committed to supporting the business objectives of its wholly owned investee companies in order that they
grow their revenues and ultimately their profitability. BTC health also continues to seek and carefully evaluate additional
investment opportunities in healthcare, more specifically, technologies and companies that in the Board’s view will benefit
from greater access to management expertise and development capital.
Environmental Regulation
The Company is not subject to any significant environmental regulation in respect of its activities.
Proceedings on Behalf of the Board
No person has applied for leave of court to bring proceedings on behalf of the Company or intervene in any proceedings to
which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or any part of those
proceedings.
Auditor & Non-Audit Services
Audit fees of $64,020 (2020: $55,844) were paid to Grant Thornton. No other fees were paid to Grant Thornton.
This directors’ report is signed in accordance with a resolution of directors made pursuant to s.298(2) of the Corporations
Act 2001.
R S Treagus, Chairman Melbourne
16 August 2022
BTC HEALTH | ANNUAL REPORT
PG 10
Corporate Governance Statement
BTC health’s board of directors (“Board”) aims to ensure that the company operates with a corporate governance
framework and practices that promote an appropriate governance culture throughout the organisation and that are
relevant, practical and cost-effective for the current size and stage of development of the business. The Board will continue
to review the framework and practices as the business size and complexity changes. The corporate governance statement
was adopted on 16 August 2022.
A description of the framework and practices is set out below, laid out under the structure of the ASX Listing Rules and the
Corporate Governance Principles (the “Principles”) and Recommendations (the “Recommendations”) 4th Edition issued by
the ASX Corporate Governance Council in February 2019.
Principle 1.
Lay solid foundations for management and oversight:
The Board is responsible for the overall corporate governance of the company. The Board acts on behalf of and is
accountable to the shareholders. The Board seeks to identify the expectations of shareholders as well as other regulatory
and ethical expectations and obligations. The Board is responsible for identifying areas of significant business risk and
ensuring mechanisms are in place to manage those risks adequately. In addition, the Board sets the overall strategic goals
and objectives, and monitors achievement of goals. In accordance with Recommendation 1.2, the board charter sets out
the roles and responsibilities of the Board and Management.
The Board has delegated the responsibility for the operation and administration of the company to the Executive Chairman
and the Company Secretary. The Board will ensure that management is appropriately qualified to discharge its
responsibilities.
The Board will ensure management’s objectives and activities are aligned with the expectations and risks identified by the
Board through a number of mechanisms including the following:
•
•
•
establishment of the overall strategic direction and leadership of the company;
approving and monitoring the implementation by management of the company’s strategic plan to achieve those
objectives;
reviewing performance against its stated objectives, by receiving regular management reports on business situation,
opportunities and risks;
• monitoring and review of the companies controls and systems including those concerned with regulatory matters to
ensure statutory compliance and the highest ethical standards; and
•
review and adoption of budgets and forecasts and monitoring the results against stated targets.
The Board sets the corporate strategy and financial targets with the aim of creating long-term value for shareholders. In
accordance with Recommendation 1.2, the Board undertakes appropriate checks before appointing a new director or putting
forward to shareholders a candidate for election and provides shareholders with all material information in its possession
relevant to a decision on whether or not to elect or re-elect a director. The company has written agreements with each
director of the company in accordance with Recommendation 1.3. The Company Secretary is accountable directly to the
Board on all matters to do with the proper functioning of the Board, in accordance with Recommendation 1.4.
At this stage of the company’s development, considering the very small size of the workforce, the Board has chosen not to
establish a formal diversity policy or formal objectives for gender diversity, as described in Recommendation
1.5. The company does not discriminate on the basis of age, ethnicity or gender and when a position becomes vacant the
company seeks to employ the best candidate available for the position. Currently all directors are male.
Given the size and nature of the company a formal process for evaluating the performance of the Board and the directors
in accordance with Recommendation 1.6 has not been developed. The company has formalized a process to review the
performance of senior executives, as described in Recommendation 1.7. Performance of senior executives includes but is
not limited to the achievement of goals set by the Board and performance behaviours in line with company values.
Principle 2.
Structure the Board to add value
The Board has not considered
it necessary or value-adding to establish a separate Nomination Committee
framework of the skills required. The Board may also engage an external consultant where appropriate to identify and
assess suitable candidates who meet the Board’s specifications. The composition of the board is discussed regularly, and
BTC HEALTH | ANNUAL REPORT
PG 11
each director may propose changes for discussion.
The company has established a skills matrix which sets out the mix of skills that the Board seeks to achieve in its
membership (recommendation 2.2).
The current Board consists of 2 non-executive directors and 1 executive director. The skills and experience of each of
the directors are detailed in the Directors’ Report. Each of the current directors has held office continuously since their
date of appointment and these details are:
Current Directors
R S Treagus appointed 4 August 2014*
J C Pilcher appointed 1 September 2015 (independent director) B A Hewett appointed 5 August 2019 (independent
director)
* R S Treagus is not considered to be independent as he is a related person to a substantial shareholder in BTC health.
The directors believe that the current structure, small size and membership profile of the Board provides the
maximum value to the business at this stage of its development, notwithstanding that they do not follow
Recommendation 2.5 as the chair is not independent. The Board will continue to assess whether this is the optimum
In the event the composition of the board
membership and structure for the business as it grows and develops.
changes, the company has formalised an induction program for new directors, as described in Recommendation 2.6.
Principle 3.
Promote ethical and responsible decision-making
The Board is committed to the highest standards of conduct and ethical behaviour in all business activities. The
company’s values underpin the performance and behaviour of directors and employees. At BTC we:
•
•
•
•
•
Deliver outcomes that make a difference
Are committed to quality and continuous improvement
Forster collaboration and value long term relationships
Are agile and act with integrity
Hold ourselves accountable to all stakeholders.
The Board established a formal Code of Conduct (Recommendation 3.2) on 19 October 2016, which requires that Board
members and employees:
• will act honestly, in good faith and in the best interests of the whole company
•
•
owe a fiduciary duty to the company as a whole
have a duty to use due care and diligence in fulfilling the functions of office and exercising the powers attached
to that office will undertake diligent analysis of all proposals placed before the Board
• will act with a level of skill expected from Directors and key executives of a publicly listed company
• will use the powers of office for a proper purpose, in the best interests of the company as a whole
• will demonstrate commercial reasonableness in decision-making
• will not make improper use of information acquired as Directors and key executives
• will not disclose non-public information except where disclosure is authorised or legally mandated
• will keep confidential information received in the course of the exercise of their duties and such information remains
the property of the company from which it was obtained and it is improper to disclose it, or allow it to be disclosed,
unless that disclosure has been authorised by the person from whom the information is provided, or required by law
• will not take improper advantage of the position of Director or use the position for personal gain or to compete with
the company
BTC HEALTH | ANNUAL REPORT
PG 12
• will not take advantage of company property or use such property for personal gain or to compete with the company
• will protect and ensure the efficient use of the company’s assets for legitimate business purposes
• will not allow personal interests, or the interest of any associated person, to conflict with the interests of the
company
•
have an obligation to be independent in judgement and actions and Directors will take all reasonable steps to be
satisfied as to the soundness of all decisions of the Board
• will make reasonable enquiries to ensure that the company is operating efficiently, effectively and legally, towards
achieving its goals
• will not engage in conduct likely to bring discredit upon the company
• will encourage fair dealing by all employees with the company’s customers, suppliers, competitors and other
employees
• will encourage the reporting of unlawful/unethical behaviour and actively promote ethical behaviour and protection
for those who report violations in good faith
• will give their specific expertise generously to the company
•
have an obligation, at all times, to comply with the spirit, as well as the letter of the law and with the principles
of this Code of Conduct
Consistent with Recommendation 3.4, the Board established a formal anti-bribery and corruption policy
(Recommendation 3.2) on 16 March 2021, which requires that Board members and employees:
• must not give, offer, promise, accept, request, authorise, assist or cover up any form of bribe, whether directly or
indirectly
•
have an obligation, at all times, to report any incident which involves bribery and or corrupt conduct
• must not engage or participate in victimisation, bullying, harassment or any other action against a person who
makes a report under this policy or is cleared of an allegation made under this policy.
The Board has adopted the following controls in its anti-bribery and corruption policy:
•
•
•
•
all gifts, entertainment or hospitality valued at $100 or more must be approved before the gift,
entertainment or hospitality is accepted. The offering or acceptance of gifts, entertainment or hospitality much
comply with legal restrictions, be done in an open and transparent manner, must not include cash, loans or cash
equivalents, and cannot be construed as an attempt to unduly influence business or government decision making.
all gifts and benefits valued at $100 or more, must be declared and recorded in the Gift and Entertainment Register
political donations shall not be made, whether in cash or kind, in support of any political parties or
candidates, or to any political cause or election fund
charitable support and donations require approval and the company must ensure that charitable
contributions are not made for the purposes of gaining commercial advantage or concealing bribery.
The Company is committed to complying with all applicable laws and regulations and acting in a manner that is consistent
with the principles of honesty, integrity, fairness and respect. The Board established a formal Whistleblower policy
(Recommendation 3.4) on 19 October 2020, which provides a safe and secure framework for any persons who are aware
of possible wrongdoing with respect to the Company Group, to be able to disclose the wrongdoing in a safe and secure
environment with confidence that they will be protected and supported. Employees are encouraged to raise concerns about
any issue or suspicion of bribery and corruption at the earliest stage.
Principle 4.
Safeguard integrity in financial reporting
With regards to Recommendation 4.1, The Board has established an Audit Committee, which currently consists of two non-
executive directors, Jon Pilcher and Bruce Hewett. Jon chairs the Committee and has extensive financial qualifications and
experience. The Audit Committee holds a majority of independent directors, although currently does not have three
members. The Audit Committee met two times during the 2022 financial year and these meetings were attended by
all members.
The current Committee operates under a charter approved by the Board on the 19 October 2016, a summary of which is
available on the BTC health website.
It is responsible for undertaking a broad review of, ensuring compliance with, and making recommendations in respect
BTC HEALTH | ANNUAL REPORT
PG 13
of, the company's internal financial controls and legal compliance obligations. It is also responsible for:
•
•
•
•
•
•
•
review of audit assessment of the adequacy and effectiveness of internal controls over the company’s
accounting and financial reporting systems, including controls over computerised systems;
review of the audit plans and recommendations of the external auditors;
evaluating the extent to which the planned scope of the audit can be relied upon to detect weaknesses in internal
control, fraud and other illegal acts;
review of the results of audits, any changes in accounting practices or policies and subsequent effects on the
financial statements and make recommendations to management where necessary and appropriate;
review of the performance and fees of the external auditor;
oversight of legal compliance including trade practices, corporations law, occupational health and safety and
environmental statutory compliance, and compliance with the Listing Rules of the ASX;
supervision of special investigations when requested by the Board;
In undertaking these tasks, the Audit Committee meets separately with management and external auditors where
required.
In accordance with Recommendation 4.2, the Board sought assurances in writing from the Executive Chairman and
the Company Secretary that in their opinion the financial records of the company for the financial year 30 June 2022
were;
a) properly maintained in accordance with section 286 of the Corporations Act 2001; and
b) the financial statements, and the notes to the financial statements, of the entity, for the financial year ended
30 June 2022:
i.
ii.
comply with Accounting Standards, the Corporations Regulations 2001 and other mandatory
professional reporting requirements; and
give a true and fair view of the entity's financial position as at 30 June 2021 and of its performance, as
represented by the results of its operations and its cash flows, for the financial year ended on that date.
The Board received those assurances on 16 August 2022.
In accordance with Recommendation 4.3, the Board ensures that its external auditor attends the AGM and is available to
answer questions from security holders relevant to the audit.
Principle 5.
Make timely and balanced disclosure
The Board recognises the importance of communicating effectively with shareholders and providing equal access to
information. The company has established the standards, protocols and requirements expected to comply with continuous
disclosure obligations under the ASX Listing Rules and the Corporations Act 2001. The Board formalised its continuous
disclosure policy on 19 October 2020 which endeavours to provide communication to third parties that a reasonable person
would expect to have a material effect on the price or value of the Company’ securities. The company will disclose to third
parties, including but not limited to shareholders, investment community, the media and the ASX which:
•
•
•
•
•
•
•
is timely; and
is factual and accurate; and
does not omit material or relevant information ; and
is expressed in a clear manner to ensure third parties are able to assess the impact of information disclosed.
The Company’s obligation to disclose price-sensitive information does not apply if, and only if, each of the following
conditions is and remains satisfied:
a reasonable person would not expect to be disclosed (because, for example, the result of disclosure would be
unreasonably prejudicial to the Company); and
the information is confidential; and
one or more of the conditions apply: it would be a breach of law to disclose the information; and/or the information
concerns an incomplete proposal or negotiation; and/or information is insufficiently definite to warrant
BTC HEALTH | ANNUAL REPORT
PG 14
disclosure; and/or information is generated for internal management purposes; and or the information is a
trade secret.
The Board may request a trading halt where confidential information is inadvertently made public and further time is
required to enable the company to prepare an appropriate public announcement; or the company is preparing to make a
major announcement. The company will provide information to the ASX under Listing Rule 3.1B to prevent or correct a
false market.
Principle 6.
Respect the rights of shareholders
The Board strives to communicate effectively with shareholders, give them ready access to balanced and understandable
information about the business and make it easy for them to participate in shareholder meetings.
In accordance with Recommendation 6.1, comprehensive information about the company and its governance is provided
via the website www.btchealth.com.au. This includes information about the Board, as well as corporate governance
policies. All announcements, presentations, financial information and meetings materials disclosed to the ASX are placed
on the website, so that current and historical information can be accessed readily.
The company’s investor relations program facilitates effective two-way communication with investors (Recommendation
6.2). The Chairman interacts with institutional investors, private investors, analysts and media on an ad hoc basis,
conducting meetings in person or by teleconference and responding personally to enquiries. The Board seeks practical and
cost-effective ways to promote informed participation at shareholder meetings (Recommendation 6.3). This includes
providing access to clear and comprehensive meeting materials and electronic proxy voting. In accordance with
Recommendation 6.4, shareholders are provided with and encouraged to use electronic methods to communicate with the
company and with the share registry.
Principle 7.
Recognise and manage risk
The Directors have not considered it necessary to form a separate Risk Committee. The Board thus retains direct
responsibility, oversight and management for material business risks. (Recommendation 7.1)
The multiple risks inherent in operating the company and managing its investments are managed by a number of means
designed to avoid or minimise any adverse material financial impact. These include:
•
•
•
reviews by the Board of the scope, practical application and thoroughness of the system of internal control and
the company’s means of recognising and protecting itself against material business risk;
reports from the company’s insurance broker concerning the adequacy of insurance cover;
reports and recommendations received from the external auditor during the process of reviewing the
accounts and internal controls.
Given that the company’s business focus is to provide patient equity capital to new Australian enterprises
endeavouring to exploit commercial opportunities in the life-sciences field, the major financial risk is that the
company’s investment will be lost or will materially lose value. This could occur under a variety of circumstances
including where the underlying enterprise subsequently fails, or commercially suffers in a significant way, e.g. due to
marketing difficulties or delays, product failure, serious management or funding problems, etc. The innovative nature
of the investee enterprises also tends to increase the investment risk involved.
The Board endeavours to reduce investment risk by a number of means, including:
•
•
•
•
•
•
requiring all investments to be made in full compliance with the Pooled Development Funds Act 1992 and the
general rationale of the PDF Program;
ensuring proper evaluation of new investment opportunities by means of a thorough due diligence
assessment;
ensuring investees have taken proper steps to secure their intellectual property rights;
ensuring each investee has a proper business plan, financial budgets and has established clear, achievable,
commercial goals;
diversifying investment over a number of different companies, each aiming at a different potential market area
or niche;
appointing a director to the board of an investee company when possible.
BTC HEALTH | ANNUAL REPORT
PG 15
The Board reviewed the company’s risk management framework and satisfied itself that it continues to be sound
on 16 August 2022. (Recommendation 7.2)
The Board considers that it is not necessary to have an internal audit function. The Board processes described above
are adequate, given the size and complexity of the business (Recommendation 7.3).
The company does not have a material exposure to economic, environmental or social sustainability risks.
(Recommendation 7.4)
Principle 8.
Remunerate fairly and responsibly
Due to the current size and structure of the company, the Board has not considered it necessary to form a
Remuneration Committee (Recommendation 8.1) and any remuneration matters are dealt with by the Board.
Particulars concerning Directors’ remuneration are set out in the Directors’ Report. The company’s current policy is
that non-executive directors receive only fixed cash remuneration.
The total remuneration pool for non-executive directors is approved by shareholders. There is currently only one
executive director and his executive fee has been determined and agreed upon by the board. The level of the fee
was determined by the directors based on professional experience, market forces and the amount of time required
to execute the role.
In accordance with Recommendation 8.3, any participants in an equity-based remuneration scheme are not
permitted to enter into any transactions (whether through the use of derivatives or otherwise) which limit the
economic risk of participating in the scheme.
BTC HEALTH | ANNUAL REPORT
PG 16
Financial Report - 30 June 2022
Statement of Profit or Loss and Other Comprehensive Income
Statement of Financial Position
Statement of Cash Flows
Statement of Changes in Equity
Notes to the Financial Statements
18
19
20
21
22
BTC health Limited is a company limited by shares, incorporated and domiciled in Australia. Its registered
office and principal place of business is:
BTC health Limited
Level 1
10 Oxley Road,
Hawthorn VIC 3122
BTC HEALTH | ANNUAL REPORT
PG 17
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2022
Revenue from continuing operations
Executive Directors fees
Non-Executive Directors fees
Listing and CHESS Fees
Legal Fees
Share based payments
Share registry fees
Audit Fees
Insurance
Filing Fees
Tax Fees
Subscriptions
Rent
Office expenses
Other expenses from operations
Loss before income tax
Income tax benefit
Loss after income tax attributable to members of
BTC health Limited
Notes
30 June
2022
$
30 June
2021
$
2
10
15
3
95,004
(97,500)
(86,250)
(48,106)
(34,554)
(200,932)
(29,942)
(64,020)
(56,599)
(6,276)
(8,380)
(6,204)
(3,251)
(246)
(28,820)
(576,076)
-
(576,076)
19,190
(180,000)
(60,000)
(34,412)
(8,360)
-
(21,130)
(55,844)
(39,188)
(5,859)
-
(1,364)
(2,491)
(1,447)
(781)
(391,686)
-
(391,686)
Total comprehensive loss for the year
(576,076)
(391,686)
Loss per share
Basic and diluted loss per share
19
(0.20) cents
(0.16) cents
The above statement of profit or loss and other comprehensive income should be read in conjunction with
the accompanying notes.
BTC HEALTH | ANNUAL REPORT
PG 18
Statement of Financial Position
As at 30 June 2022
Current Assets
Cash and cash equivalents
Loans to investee companies
Other assets
Total Current Assets
Non-Current Assets
Other financial assets
Total Non-Current Assets
Total Assets
Current Liabilities
Trade and other payables
Unclaimed monies
Total Current Liabilities
Total Liabilities
Net Assets
Equity
Issued capital
Other reserves
Accumulated losses
Total Equity
Notes
30 June
2022
$
30 June
2021
$
4
7
5
6
8
2,170,493
-
27,188
2,197,681
10,819,890
10,819,890
13,017,571
51,026
104,581
155,607
155,607
12,861,964
2,368,975
2,614,219
930
4,984,124
8,000,100
8,000,100
12,984,224
2,040,535
106,581
2,147,116
2,147,116
10,837,108
9
10
11
55,665,612
200,932
(43,004,580)
12,861,964
53,265,612
171,857
(42,600,361)
10,837,108
The above statement of financial position should be read in conjunction with the accompanying notes.
BTC HEALTH | ANNUAL REPORT
PG 19
Statement of Cash Flows
For the year ended 30 June 2022
Cash Flows from Operating Activities
Receipts from customers
Interest received
Payments to suppliers and directors
Transfer from unclaimed monies account
Net cash used in operating activities
Cash Flows from Investing Activities
Proceeds on sale of Investments
Net Loans issued to investee companies
Equity investment to investee companies
Net cash used in investing activities
Cash Flows from Financing Activities
Share placement
Capital raising costs
Net cash generated by financing activities
Notes
30 June
2022
$
30 June
2021
$
12
6
67,755
636
(459,302)
(2,000)
(392,911)
-
(205,571)
(2,000,000)
(2,205,571)
2,500,000
(100,000)
2,400,000
(198,482)
2,368,975
68,019
857
(434,882)
(146)
(366,152)
500,000
(515,162)
-
(15,162)
-
-
-
(381,314)
2,750,289
4
2,170,493
2,368,975
Net increase/ (decrease) in cash and cash equivalents held
Cash and cash equivalents at the beginning of the
financial year
Cash and cash equivalents at the end of the Financial Year
The above statement of cash flows should be read in conjunction with the accompanying notes.
BTC HEALTH | ANNUAL REPORT
PG 20
Statement of Changes in Equity
For the year ended 30 June 2022
At 1 July 2020
Loss for the year
Total comprehensive (loss) for the year
Transaction with owners in their capacity as
owners:
Share placement
(net of capital raising costs)
Share based payments
Expiry of share options
Issued
capital
$
Accumulated
losses
$
53,265,612
(42,251,664)
Other
reserves
$
214,846
-
-
-
-
-
(391,686)
(391,686)
-
-
42,989
-
-
-
-
(42,989)
Total
$
11,228,794
(391,686)
(391,686)
-
-
-
At 30 June 2021
53,265,612
(42,600,361)
171,857
10,837,108
At 1 July 2021
Loss for the year
Total comprehensive (loss) for the year
Transaction with owners in their capacity as
owners:
Share placement
(net of capital raising costs)
Share based payments
Expiry of share options
53,265,612
(42,600,361)
171,857
10,837,108
-
-
(576,076)
(576,076)
2,400,000
-
-
-
-
171,857
-
-
-
200,932
(171,857)
(576,076)
(576,076)
2,400,000
200,932
-
At 30 June 2022
55,665,612
(43,004,580)
200,932
12,861,964
The above statement of changes in equity should be read in conjunction with the accompanying notes.
BTC HEALTH | ANNUAL REPORT
PG 21
Note 1 Summary of Significant Accounting Policies
The Financial Report of BTC health Limited for the year ended 30 June 2022
This general purpose financial report has been prepared in accordance with the requirements of Australian Accounting
Standards (including Australian Accounting Interpretations) and the Corporations Act 2001. The financial report was
authorised for issue in accordance with a resolution of the directors on 16 August 2022.
BTC health Limited is a company limited by shares incorporated in Australia whose shares are publicly traded on the
Australian Securities Exchange.
Basis of Preparation
The financial statements are prepared in accordance with the historical cost convention, except for certain assets which, as
noted, are at fair value.
Both the functional currency and presentation currency of BTC health Limited is Australian dollars (AUD). For the purpose
of preparing the financial statements, the Company is a for-profit entity.
Statement of Compliance
Compliance with Australian Accounting Standards ensures that the financial report, comprising the financial statements
and notes, complies with International Financial Reporting Standards (‘IFRS’).
Adoption of New and Revised Accounting Standards
New and amended Australian Accounting Standards that are effective for the current year
The company has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the
Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The new, revised or
amending Accounting Standards and Interpretations adopted do not have a material effect on the company.
New and revised Australian Accounting Standards in issue but not yet effective
At the date of authorisation of these financial statements, several new, but not yet effective, Standards and
amendments to existing Standards, and Interpretations have been published by the IASB. The company has
considered Standards, amendments and Interpretations which have been issued but are not yet effective, identifying
the following which are relevant to the company:
• AASB 2020-1 Amendments to Australian Accounting Standards – Classification of Liabilities as current or non-current
• AASB 2021-2 Amendments to Australian Accounting Standards – Disclosure of Accounting Policies and Definition of
Accounting Estimates
When these amendments are first adopted for the year ending 30 June 2024 there will be no material impact on the
financial statements.
Other Standards, amendments and Interpretations which have been issued but are not yet effective are not relevant to the
company, or their impact is editorial only.
Significant Accounting Policies
The following significant accounting policies have been adopted in the preparation and presentation of the financial report.
a) Investment Entity
The Company meets the definition of investment entities which are exempt from consolidation under AASB 10 Consolidated
Financial Statements. Instead of consolidating controlled investments the Company measures its investments at fair value
in the Statement of Financial Position and recognises changes in the fair value through the profit or loss.
b) Revenue Recognition
The Company recognises revenue from management fees for services rendered to investee companies.
Revenue is measured based on the consideration to which the Company expects to be entitled in a contract with a customer
and excludes amounts collected on behalf of third parties. Management fee revenue is recognised over time as the
customer simultaneously receives the benefits provided by the entity’s performance.
BTC HEALTH | ANNUAL REPORT
PG 22
c) Interest Income
Interest income is recognised as the interest accrues (using the effective interest method, which is the rate that exactly
discounts estimated future cash receipts through the expected life of the financial instrument) to the net carrying amount
of the financial asset.
d) Income Tax
Current tax payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of
comprehensive income because of items of income or expense that are taxable or deductible in other years and items that
are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or
substantively enacted by the end of the reporting period.
Deferred income tax is provided on all temporary differences at the statement of financial position date between the tax
bases of assets and liabilities and their carrying amounts for financial reporting purposes. Deferred income tax liabilities are
recognised for all taxable temporary differences except where the deferred income tax liability arises from the initial
recognition of an asset or liability in a transaction that is not a business combination and, at the time of the transaction,
affects neither the accounting profit nor taxable profit or loss.
Deferred income tax assets are recognised for all deductible temporary differences, carry-forward of unused tax credits and
unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible
temporary differences, and the carry-forward of unused tax credits and unused tax losses can be utilised.
The carrying amount of deferred income tax assets is reviewed at each balance sheet date and reduced to the extent that
it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to
be utilised. Deferred income tax assets and liabilities are measured at the tax rates expected to apply to the year when the
asset is realised, or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted
at the statement of financial position date.
e) Financial Instruments
Financial assets and financial liabilities are recognised in the Company’s statement of financial position when the Company
becomes a party to the contractual provisions of the instrument.
Financial assets and financial liabilities are initially measured at fair value. Fair value is the price that would be received to
sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date,
regardless of whether that price is directly observable or estimated using another valuation technique. Transaction costs
that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets
and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets
or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of
financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss. In
estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability
if market participants would take those characteristics into account when pricing the asset or liability at the measurement
date. Fair value for measurement and/or disclosure purposes in these financial statements is determined on such a basis,
except for share-based payment transactions that are within the scope of AASB 2.
In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the
degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value
measurement in its entirety, which are described as follows:
•
•
•
Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can
access at the measurement date;
Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability,
either directly or indirectly; and
Level 3 inputs are unobservable inputs for the asset or liability.
Financial Assets
All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way
purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established
by regulation or convention in the marketplace.
BTC HEALTH | ANNUAL REPORT
PG 23
All recognised financial assets are measured subsequently in their entirety at either amortised cost or fair value, depending
on the classification of the financial assets.
Classification of financial assets
The company classifies its financial assets as debt instruments measured subsequently at amortised cost only if both the
following criteria are met:
•
the financial asset is held within a business model whose objective is to hold financial assets in order to collect
contractual cash flows; and
the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of
principal and interest on the principal amount outstanding.
•
Financial liabilities and equity
Classification as debt or equity
Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the
contractual arrangements and the definitions of a financial liability and an equity instrument.
Equity instruments
An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all its
liabilities. Equity instruments issued by the Group are recognised at the proceeds received, net of direct issue costs.
Financial liabilities
All the Company’s financial liabilities are measured subsequently at amortised cost using the effective interest method.
Cash and cash equivalents
f)
Cash and short-term deposits in the statement of financial position comprises of cash at bank and in hand and short-term
deposits with an original maturity of three months or less that are readily convertible to known amounts of cash and which
are subject to insignificant risk of change in value. For the purposes of the Statement of Cash Flows, cash and cash
equivalents consist of cash and cash equivalents as defined above.
Share-based payments
g)
Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of
the equity instruments at the grant date. The fair value excludes the effect of non-market- based vesting conditions.
The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis
over the vesting period, based on the Company’s estimate of the number of equity instruments that will eventually vest.
At each reporting date, the Company revises its estimate of the number of equity instruments expected to vest as a result
of the effect of non-market-based vesting conditions. The impact of the revision of the original estimates, if any, is
recognised in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment
to reserves.
Equity-settled share-based payment transactions with parties other than employees are measured at the fair value of the
goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at
the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty
renders the service.
Earnings / (Loss) per share
Basic earnings / (loss) per share
h)
I.
Basic earnings per share is determined by dividing net profit after income tax attributable to members of the company,
excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares
outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year.
II. Diluted earnings / (loss) per share
Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the
after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the
weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential
ordinary shares.
BTC HEALTH | ANNUAL REPORT
PG 24
i)
j)
Goods and services tax (GST)
Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not
recoverable from the Australian Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition
of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown
inclusive of GST. Cash flows are presented in the statement of cash flows on a net basis.
Critical accounting judgments, estimates and assumptions
In applying the Company's accounting policies, management continually evaluates judgments, estimates and assumptions
based on experience and other factors, including expectations of future events that may have an impact on the Company.
All judgments, estimates and assumptions made are believed to be reasonable based on the most current set of
circumstances available to management. Actual results may differ from the judgments, estimates and assumptions.
Determination of investment entity status
BTC health was admitted to the Australian Securities Exchange as an investment entity and continues to meet the criteria
set out under AASB 10 Consolidated Financial Statements to qualify as an investment entity. This judgement is reconsidered
by management and the Board at each reporting date. Consequently, investee companies are not consolidated in BTC
health’s financial statements. Instead, the investments held by BTC health in these companies is recorded as an investment
held at fair value through profit or loss in BTC health’s financial statements.
Valuation of investments
Investments in investee companies are held at fair value. These investments are ‘Level 3’ in the fair value hierarchy, based
on unobservable inputs, as the investee companies are unlisted and not traded in an active market. Consequently, they are
valued in accordance with the directors’ valuations. The directors have used the historical and budgeted performance of
the investee companies as the basis for the valuation of the investments, adjusted for reasonable assumptions about future
performance (such as estimated cash flows, projected business growth plans and other market data available).
Should the assumptions used by the directors change in subsequent periods, the fair value may be impacted and accounted
for through the profit or loss. Further disclosure as required by AASB 13 is set out in Note 18.
No other critical judgements, other than in the determination of accounting policies as set out within this note, have been
made.
Note 2
Revenues from Ordinary Activities
Interest income
Management Fee
Other revenue
Closing balance
30 June
2022
$
30 June
2021
$
636
94,368
-
95,004
857
13,333
5,000
19,190
BTC HEALTH | ANNUAL REPORT
PG 25
Note 3 Income Tax
Major components of income tax expense for the years ended 30 June 2021 and 2020 are:
30 June
2022
$
30 June
2021
$
-
-
-
-
-
-
Statement of Profit or Loss and other Comprehensive Income
Current Income
Current income tax benefit
Deferred Income Tax
Relating to origination and reversal of temporary differences
Income tax expense reported in the statement of profit or loss and
other comprehensive income
A reconciliation of income tax expense / (benefit) applicable to
accounting profit / (loss) before income tax at the statutory income tax
rate to income tax expense at the company’s effective income tax
rate for the years ended 30 June 2022 and 2021 is as follows:
Accounting profit / (loss) before tax from continuing operations
(576,076)
(391,686)
At the statutory income tax rate of 25% (2021: 25%)
(144,019)
(97,922)
Temporary differences and tax losses not brought to account as a
deferred tax asset
Permanent differences
8,071
-
95
-
Temporary differences and tax losses not brought to account as a
deferred tax asset to retained earnings
(152,090)
(97,827)
At effective income tax rate of (0%) (2021: (0%))
Income tax expense reported in statement of profit or loss
-
-
-
-
The Company is a Pooled Development Fund (PDF) and is taxed at 15% on income and gains from investments in
small to medium enterprises and taxed at 25% on all other income.
30 June
2022
$
30 June
2021
$
Unrecognised deferred tax losses
Deferred tax assets have not been recognised in respect of the following
items:
Tax Losses – Revenue
Temporary differences
Tax Losses – Capital
Closing balance
6,851,918
72,373
225,000
7,149,291
6,707,899
64,302
225,000
6,997,201
The tax losses do not expire under current tax legislation. Deferred tax assets have not been recognised in respect of
this item because it is not probable that future taxable profit will be available in the immediate future against which
the company can utilise the benefits.
BTC HEALTH | ANNUAL REPORT
PG 26
Note 4 Cash and cash equivalents
Cash at bank and on hand
Closing balance
30 June
2022
$
2,170,493
2,170,493
30 June
2021
$
2,368,975
2,368,975
Cash at bank and on hand earns interest at floating rates based on daily bank deposit rates.
Note 5 Other assets
Prepayments
Trade debtors
Closing balance
30 June
2022
$
30 June
2021
$
575
26,613
27,188
930
-
930
Prepayments comprise insurance policies which are amortised on a straight line basis. Trade
debtors are all related party transactions from BTC health’s subsidiaries and relate to Management
Fees invoiced in June. All trade debtors are payable with 30 days.
Note 6 Other financial assets
Other financial assets carried at fair value through profit or loss
Non - Current
BioImpact Pty Ltd
BTC Speciality Health Pty Ltd
Sensear Pty Ltd
30 June
2022
$
30 June
2021
$
2,883,975
7,935,915
-
2,000,100
6,000,000
-
Total Non-Current other financial assets
10,819,890
8,000,100
Closing balance
10,819,890
8,000,100
Summary of changes in investments in financial assets
Opening
Revaluation of unlisted investment
Additions
Disposals
Closing balance
8,000,100
-
2,819,790
-
10,819,890
6,500,100
-
2,000,000
(500,000)
8,000,100
BTC health Limited, as an investment entity, has applied the exception to consolidation and instead
accounts for its investments in its subsidiaries at fair value through profit or loss in accordance with AASB
10.
BioImpact Pty Ltd is 100% owned by BTC health Limited. BioImpact licenses and holds intellectual property
BTC HEALTH | ANNUAL REPORT
PG 27
rights for healthcare products for commercialisation in the Asia/Pacific region. Technologies and products
are sourced from international supply partners. During the year, BTC health limited acquired 883,875
new shares in BioImpact Pty Ltd for $1 each. The funds were used by BioImpact to fully repay the loan
payable to BTC health Limited. As at 30 June 2022, there were nil loans outstanding from BioImpact Pty
Ltd.
BTC Speciality Health Pty Ltd is 100% owned by BTC health Limited. BTC Speciality Health is an established
distributor of BTC health group’s medical devices and consumables in the Australian and New
Zealand public and private hospital market. During the year, BTC health limited acquired 183,879,529 new
shares in BTC Speciality Health Pty Ltd for $1.03 each. The funds were used by BTC Speciality Health
Pty Ltd to fully repay the loan payable to BTC health Limited. As at 30 June 2022, there were nil loans
outstanding from BTC Speciality Health Pty Ltd.
BioImpact and BTC Speciality Health’s principal place of business is Level 1, 10 Oxley Road, Hawthorn VIC
3122.
Unlisted shares
The fair value of each unlisted investment is determined by directors’ valuation, which is based on their
experience in the industry. These investments are considered to be Level 3 in the fair value hierarchy. The
directors have used assumptions, such as estimated cash flows, project plans and other market data
available in determining their valuation of the unlisted investments. Should these assumptions change in
subsequent periods the fair value may be impacted and accounted for through the profit or loss. The
directors have used several different valuation tools to determine the fair value of the investee
companies, including discounted cash flows and multiples of revenues and profits.
Further disclosures required by AASB 13 Fair Value Measurement are included at Note 18.
Note 7 Loans to investee companies
Loans to investee companies
BioImpact Pty Ltd
BTC Speciality Health Pty Ltd
Closing balance
30 June
2022
$
30 June
2021
$
-
-
-
678,304
1,935,915
2,614,219
Loans issued to BioImpact Pty Ltd and BTC Speciality Health Pty Ltd were fully repaid during the year through
the issuance of equity in the investee companies. Loans are non-interest bearing and have no fixed terms of
repayment. The estimated loss allowance for loans to investee companies at 30 June 2022 is $nil (2021: $nil).
Note 8 Trade and other payables
Current
Trade creditors
Accruals
Closing balance
30 June
2022
$
30 June
2021
$
5,576
45,450
51,026
39,985
2,000,550
2,040,535
Trade and other payables are non-interest bearing and are generally settled on 30-day terms.
BTC HEALTH | ANNUAL REPORT
PG 28
Note 9
Issued Capital
a) Ordinary Shares
Issued and fully paid – Opening Balance
246,132,068
53,265,612
246,132,068
53,265,612
2022
Shares
2022
$
2021
Shares
2021
$
Share Placement 9 July 2021
Capital raising costs
32,015,233
-
2,241,066
(100,000)
Share Placement 12 July 2021
3,699,053
258,934
-
-
-
-
-
-
Closing Balance
281,846,354
55,665,612
246,132,068
53,265,612
Ordinary shares
b)
Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the company
in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of
ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share
is entitled to one vote. The company does not have authorised capital or par value in respect of its issued capital.
Note 10 Share Based Payments / Other Reserves
Opening balance
Options – Additions
Expiry of share options
Closing balance
30 June
2022
$
171,857
200,932
(171,857)
200,932
30 June
2021
$
214,846
-
(42,989)
171,857
Unlisted options are valued using the Black-Scholes valuation model and are expensed over the vesting period of
the options. The Employee Share Option Plan was approved at the Annual General Meeting on 23 November 2021.
A total of 9,000,000 share options were issued and vested on 23 November 2021. At the date of the report, there
are 9,000,000 unlisted ordinary shares under option of which 2,999,999 had vested (2021: 5,000,000). A total of
5,000,000 share options expired on 21 June 2022.
The following share-based payment arrangements in the form of share options were in existence during the
current reporting period:
2019 Financial Year Grant
The below options were granted in relation to the settlement of a short term loan that was issued and repaid in
the financial year ended 30 June 2019. There has been no alteration of the terms and conditions of the
above share-based payment arrangements since the grant date.
Options
Granted
Grant
Date
Grant date
fair value
$
5,000,000
21.06.2019
0.03
Exercise
Price
$
0.10
Expiry
Date
Vesting
Date
21.06.2022
21.06.2019
All options outstanding from the 2019 Financial Year Grant expired in the current year. Nil options were exercised.
BTC HEALTH | ANNUAL REPORT
PG 29
2022 Financial Year Grant
The below options were granted under the Employee Share Option Plan, approved at the Company’s
Annual General Meeting on 23 November 2021. There have been no alteration of terms and conditions
of the above share-based payment arrangements since the grant date.
Options
Granted
2,999,999
2,999,999
3,000,002
Grant
Date
23.11.2021
23.11.2021
23.11.2021
Grant date
fair value
$
0.038
0.033
0.030
Exercise
Price
$
0.12
0.12
0.12
Expiry
Date
23.11.2026
23.11.2027
23.11.2022
Vesting
Date
23.11.2021
23.11.2022
23.11.2023
The opening number of options at 1 July 2021 was 5,000,000. At the date of the report, there are
9,000,000 unlisted ordinary shares under option (2021: 5,000,000), with 9,000,000 options granted and
5,000,000 options which expired during the year. At the date of the report, nil share options had been
exercised.
Fair value of share options granted in the year
The weighted average fair value of the share options granted during the 2022 financial year is $0.038 (2019:
$0.034). Options were priced using a Black Scholes option pricing model. Where relevant, the expected life
used in the model has been adjusted based on management’s best estimate for the effects of non-
transferability and exercise restrictions, including the probability of meeting service conditions attached
to the option. Expected volatility was based on the historical share price volatility in the 3 year period
leading up to the grant date.
Note 11 Accumulated Losses
Accumulated losses at the beginning of the year
Expiry of share options
Total comprehensive loss for the year
Accumulated losses at the end of the year
30 June
2022
$
30 June
2021
$
(42,600,361)
171,857
(576,076)
(42,251,664)
42,989
(391,686)
(43,004,580)
(42,600,361)
Note 12 Reconciliation of Operating Loss after Income Tax to the Net Cash Flow from
Operating Activities
Loss after income tax
Adjustment for:
Increase in valuation of unlisted investment
Share based payments
Increase / (Decrease) in trade and other payables
(Increase) / Decrease in other assets
Increase / (Decrease) in unclaimed monies account
Net cash used in operating activities
8
5
30 June
2022
30 June
2021
(576,076)
(391,686)
-
200,932
10,491
(26,258)
(2,000)
-
-
(80,874)
106,554
(146)
(392,911)
(366,152)
BTC HEALTH | ANNUAL REPORT
PG 30
Note 13 Subsequent Events
No matters or circumstances have arisen since the end of the financial year which significantly affected or
may significantly affect the operations of the company, the results of those operations or the state of
affairs of the company in future financial years.
Note 14 Key Management Personnel
Name and position of key management personnel of the company in office at any time during the financial year:
R Treagus – Executive Chairman
J Pilcher – Non-executive Director
B Hewett – Non-executive Director
S Papworth – CFO and Company Secretary
Remuneration of key management personnel
Information on remuneration of key management personnel is set out in the Remuneration Report in the
Directors Report.
Short term benefits
Post-employment benefits
Share based payments
Closing balance
30 June
2022
$
30 June
2021
$
179,091
4,659
133,955
317,705
236,530
3,470
-
240,000
There are no other long-term benefits and no termination benefits for key management personnel.
Note 15
Remuneration of Auditors
Grant Thornton
Remuneration for audit or review of the financial statements
Total audit remuneration
Note 16 Related Party Disclosures
30 June
2022
$
30 June
2021
$
64,020
55,844
64,020
55,844
Transactions with, and amounts owing to and from, the investee companies during and at 30 June 2022 were as
follows:
Investee Company
BTC Speciality Health Pty Ltd
BioImpact Pty Ltd
Revenue
$94,368
-
Expenses
Receivable
Payable
$3,251
-
$26,613
-
-
-
BTC HEALTH | ANNUAL REPORT
PG 31
Comparatives for the above are as follows:
Investee Company
Revenue
Expenses
Receivable
Payable
BTC Speciality Health Pty Ltd
BioImpact Pty Ltd
-
-
$2,491
-
$26,613
-
-
-
In June 2021, BTC health accrued $2,000,000 investment in BioImpact Pty Ltd. This was paid during the 2022 financial
year.
Amounts outstanding at 30 June 2022 are unsecured and repayable on demand (2021: unsecured and repayable on
demand). No provision for doubtful debts has been recognised related to amounts outstanding (2021: none).
The company held loans to investee companies of $nil (2021: $2,614,219). During the year, $2.7m loans were
converted to equity in the investee companies. Further disclosures pertaining to investee company loans can be
obtained in note 7.
Related party transactions with directors and key management personnel are disclosed in the Remuneration Report
and in Note 14.
Fees to the Chairman were paid through PharmaConnect Pty Ltd, which is a related entity. No material transactions
other than those disclosed in the Remuneration Report pertaining to the Chairman occurred with PharmaConnect
Pty Ltd in the year-ended 30 June 2022 (2021: none).
While other related party relationships have been identified by management, there were no material transactions
with those related parties in the year-ended 30 June 2022 (2021: none). No other related parties where control
exists have been identified other than as set out above.
Note 17 Operating Segments
Operating segments have been identified on the basis of internal reports of the Company that are regularly reviewed
by the chief operating decision maker in order to allocate resources to the segments and to assess their performance.
The chief operating decision maker has been identified as the Executive Chairman. BTC health has a single operating
segment, being the making and managing of investments in healthcare ventures.
Note 18 Financial Risk Management Objectives and Policies
Financial Risk Management Overview
The company has exposure to the following risks from the use of financial instruments – interest rate risk, credit risk,
liquidity risk and market price risk. This note presents information about the Company’s exposure to each of the
above risks, their objectives, policies and processes for measuring and managing risk, and the management of
capital.
The Board of Directors has overall responsibility for the establishment and oversight of the risk management
framework. The board reviews regularly the adequacy of the risk management framework in relation to the
risks faced by the company. The company’s principal financial instruments comprise cash and short- term
deposits and financial assets. The company has other financial instruments such as trade debtors and trade creditors
that arise directly from its operations. The company’s policy in relation to the valuation of investments
traded on organised markets, and unlisted investments has been described in Note 1(e).
Interest Rate Risk
Interest rate risk is the risk that the value of a financial instrument or cash flows associated with the instrument will
fluctuate due to changes in market interest rates. Interest rate risk arises from fluctuations in interest bearing
financial assets and liabilities that the company uses. The company’s financial assets which are affected by interest
rate risk are the company’s cash and cash equivalents and term deposits held. The company manages its interest risk
by using a mix of fixed and variable rates and trades only with recognised credit worthy third parties.
BTC HEALTH | ANNUAL REPORT
PG 32
The following table sets out the carrying amount, by maturity, of the financial instruments that are exposed to
interest rate risk:
30 June 2022
Financial Assets
Cash
Total financial assets
Financial liabilities -
Trade and other payables
Unclaimed monies
Total financial liabilities
Net Financial Assets
30 June 2021
Financial Assets
Cash
Total financial assets
Financial liabilities -
Trade and other payables
Total financial liabilities
Net Financial Assets
Balance
$
Interest
Rate
Weighted Average
Effective Interest Rate
2,170,493
2,170,493
51,026
104,581
155,607
2,014,866
Floating
0.01%
N/A
N/A
-
-
Floating
0.01%
N/A
-
2,368,975
2,368,975
2,040,535
2,040,535
328,440
Fair value sensitivity analysis for fixed rate instruments
The company does not account for any fixed rate financial assets and liabilities at fair value through profit or loss.
Therefore, a change in interest rates at the reporting date would not affect profit or loss.
Cash flow sensitivity analysis for variable rate instruments
If interest rates had been 50 basis points higher/lower and all other variables were held constant, the
company’s:
Loss for the year ended 30 June 2021 would decrease/increase by $32,787 (2021: decrease/increase by $50,236).
This is mainly attributable to the company’s exposure to interest rates on its variable rate savings.
Credit Risk
Credit risk is the risk of financial loss to the company if a customer or counterparty to a financial instrument fails
to meet its contractual obligations and arises principally from the company's cash and cash equivalents, other
assets and loans to investee companies. The company’s maximum exposure to credit risk at balance date in
relation to each class of recognised financial asset is the carrying amount of these assets.
Liquidity Risk
Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The
Company’s approach to managing liquidity is to ensure, as far as possible, that it will always have sufficient liquidity
to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses
or risking damage to the Company’s reputation. The following are the contractual maturities of financial liabilities:
BTC HEALTH | ANNUAL REPORT
PG 33
30 June 2022
Trade and other payables
Unclaimed monies
30 June 2021
Trade and other payables
Unclaimed monies
Carrying
amount
Contractual
cash flows
6 months or
less
$
(51,026)
(104,589)
(155,607)
$
(51,026)
(104,589)
(155,607)
$
(51,026)
(104,589)
(155,607)
(2,040,535)
(106,581)
(2,147,116)
(2,040,535)
(106,581)
(2,147,116)
(2,040,535)
(106,581)
(2,147,116)
Greater than 6
months, less
than 1 year
Greater than
1 year
$
-
-
-
-
-
-
$
-
-
-
-
-
-
Fair Value of Financial Assets and Liabilities
There is no difference between the fair values and the carrying amounts of the company’s financial instruments.
The company has no unrecognised financial instruments at balance date.
Market Price Risk
Equity price risk arises from financial assets held at fair value through profit or loss held as a part of the company's
operations. Investments within the portfolio are managed on an individual basis and all buy and sell decisions are
approved by the Board of Directors. The primary goal of the Company’s investment strategy is to maximise
investment returns on sale of investments. Unlisted investments are designated as a financial asset held at
fair value through profit or loss. Their performance is actively monitored, and they are managed on a fair value
basis.
Sensitivity analysis on changes in market equity prices
A change of 20% (based on the Board’s assessment of similar movements in the life sciences industry) in equity
prices at the reporting date would have increased (decreased) equity and profit or loss by the amounts
shown below. The analysis is performed on the same basis for 2021.
30 June 2022
Financial assets carried at fair value
through profit or loss before tax:
Unlisted investments
Profit or loss
before tax
Equity
Carrying
Value
20%
increase
20%
decrease
20%
increase
20%
decrease
$
$
$
$
$
10,819,890 2,163,978
2,163,978
(2,163,978)
(2,163,978)
2,163,978
2,163,978
(2,163,978)
(2,163,978)
30 June 2021
Financial assets carried at fair value
through profit or loss before tax:
Unlisted investments
Profit or loss
Before tax
Equity
Carrying
Value
20%
increase
20%
decrease
20%
increase
20%
decrease
8,000,100 1,600,020
1,600,020
(1,600,020)
(1,600,020)
1,600,020
1,600,020
(1,600,020)
(1,600,020)
BTC HEALTH | ANNUAL REPORT
PG 34
Fair value of financial instruments: Valuation techniques and assumptions applied for the purposes of
measuring fair value
The fair values of unlisted investments are determined in accordance by directors’ valuations, which are based on their
experience in the industry. These investments are considered to be Level 3 in the fair value hierarchy. Directors have
used assumptions, such as estimated cash flows, project plans and other market data available in determining their
valuation of unlisted investments. Directors have reviewed discounted cash flows and multiple of revenue and profit
calculations to determine the fair value holding costs of the investments.
Name of Investment
Core Activity
Basis of Valuation
BioImpact Pty Ltd
In licence speciality
pharmaceuticals and
medical devices
Valuation is based on an ‘income approach’, being a present
value technique taking into account the future cash flows
expected from the investment.
BTC Speciality Health Pty Ltd
Commercialisation and
distribution
of pharmaceuticals and
medical devices
The approach has been consistent year-on-year. The company
reviews it valuation policy at each reporting date to ensure it
remains appropriate. The valuation model used by the company
is updated at each reporting date, taking into account changes
in assumptions in the period, updated financial results and
budgeted performance of the investee companies, and analysis
of past performance against initial forecasts.
Valuation is based on an ‘income approach’, being a present
value technique taking into account the future cash flows
expected from the investment.
The approach has been consistent year-on-year. The company
reviews it valuation policy at each reporting date to ensure it
remains appropriate. The valuation model used by the company
is updated at each reporting date, taking into account changes in
in the period, updated financial results and
assumptions
budgeted performance of the investee companies, and analysis
of past performance against initial forecasts.
The key inputs used in the determination of the fair value of the investments includes the execution of strategic plans
which are commercial in confidence. The strategic plans considers cashflow forecasts for the on-market portfolio which
are currently marketed and distributed by BTC health’s investee companies. Risk weighted pipeline cash flows for expected
future licensed products have not been included in the fair value assumptions. BTC’s investee companies have a range of
pipeline products which will require little or no investment and therefore the net margin net of working capital may flow
through into operating cashflows, should these contracts be executed. The uplift from such products at modest sales
of $0.25m per annum would yield a 6% surplus on the current fair value. In the event the number of elective
surgeries reduced 5% against forecast, the fair value of investments may be impaired -5%; although the expectation of
this occurring in the medium to long term is considered low, given the commitment from both State and Federal
Governments to invest in hospital health care and reduce elective surgery wait times.
A pre-tax discount rate of 12% has been used to derive the Net Present Value of cashflows. The discount rate has not
changed over prior periods and considers the Weighted Average Cost of Capital (WACC). Given BTC health and it’s investee
companies do not leverage debt to fund it’s growth plans and therefore the discount rate reflects returns expected
by shareholders. The discount rate from other healthcare companies listed on the Australian Securities and Exchange
ranges between 12-15%, although these companies are not comparable to BTC health given they are highly geared
and the healthcare products sold may attract higher risk given the Research and Development (R&D) costs
associated with enabling the product to be registered with the Therapeutic Goods Administration (TGA). The products
licensed by BTC health’s investee companies do not require R&D nor clinical trials to gain approval and listing on the
TGA. A increase/decrease in the discount rate by 100 bpts would result in a change in valuation of +8/- 5%.
There were no gains or losses recognised in the profit or loss for the year-ended 30 June 2022 (2021: $nil). During the year,
loans outstanding from the investee companies were converted to additional equity in the investee companies (Note 16).
BTC HEALTH | ANNUAL REPORT
PG 35
Fair value measurements recognised in the statement of financial position:
The following table provides an analysis of financial instruments that are measured subsequent to initial recognition
at fair value, grouped into Levels 1 to 3 based on the degree to which the fair value is observable.
a)
Level 1 fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical
assets or liabilities.
Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1
that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset
or liability that are not based on observable market data (unobservable inputs).
b)
c)
30 June 2022
Financial assets
Unlisted investments– Financial assets carried at
fair value through profit or loss
30 June 2021
Financial assets
Unlisted investments– Financial assets carried at
fair value through profit or loss
There were no transfers between levels during the year.
Level 1
Level 2
Level 3
Total
$
-
-
-
-
$
-
$
$
10,819,890 10,819,890
10,819,890 10,819,890
8,000,100
8,000,100
8,000,100
8,000,100
Reconciliation of Level 3 fair value measurements of financial assets
Opening balance
Total gains or losses:
acquisitions
divestments
investment fair value adjustment
-
-
-
Closing balance
2022
Total
$
8,000,100
2,819,790
-
-
10,819,890
2021
Total
$
6,500,100
2,000,000
(500,000)
-
8,000,100
Significant assumptions used in determining fair value of financial assets and liabilities
The fair value of unlisted investments is determined by directors’ valuations and assumptions, such as impacts on
estimated cash flows, project plans and market data available. Significant assumptions used in determining the
fair value of unlisted investments are set out in Note 1(j).
Capital risk management
The Company objectives when managing capital are to safeguard the Company’s ability to continue as a going
concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an
optimal capital structure to reduce the cost of capital. The management of the Company's capital is performed
by the Board. The company is not subject to externally imposed capital requirements. The Company’s
overall strategy remains unchanged from 2021.
The capital structure of the Company consists of cash and cash equivalents and equity attributable to equity
holders, comprising issued capital, reserves and retained earnings. Operating cash flows are used to maintain
and expand operations, as well as to make routine expenditures such as tax and general administrative outgoings.
BTC HEALTH | ANNUAL REPORT
PG 36
Categories of financial instruments
Financial assets
Cash and cash equivalents
Other assets
Loans to investee companies
Financial assets carried at fair value through profit or loss
Financial liabilities
Trade and other payables
Unclaimed monies
Note 19 Loss Per Share
Basic and diluted loss per share, based on the
after tax loss of $391,686 (2020: ($283,036)) *
Weighted average number of ordinary shares used
as the denominator in calculating basic earnings per
share
30 June 2022
$
30 June 2021
$
2,170,493
27,188
-
10,819,890
(51,026)
(104,581)
2,368,975
930
2,614,219
8,000,100
(2,040,535)
(106,581)
30 June 2022
30 June 2021
(0.20) cents per share
(0.16) cents per share
281,846,354 shares
246,132,068 shares
*The options issued are not included in the diluted EPS as they are non-dilutive.
Note 20 Contingent Liabilities
There were no contingencies of which the company is aware as at the date of this report (2021: none).
BTC HEALTH | ANNUAL REPORT
PG 37
Directors’ Declaration
The directors declare that,
a)
b)
c)
in the director’s opinion, there are reasonable grounds to believe that the company will be able
to pay its debts as and when they become due and payable,
in the director’s opinion, the attached financial statements are in compliance with International
Financial Reporting Standards as disclosed in Note 1 to the financial statements,
in the director’s opinion, the attached financial statements and notes thereto are in accordance
with the Corporations Act 2001, including compliance with accounting standards and giving a
true and fair view of the financial position and performance of the entity, and
d)
the directors have been given the declarations required by s.295A of the Corporations Act 2001.
This declaration is made in accordance with a resolution of the board of directors pursuant to section 295(5) of
the Corporations Act 2001.
R S Treagus
Chairman
Melbourne
16 August 2022
BTC HEALTH | ANNUAL REPORT
PG 38
Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222
Auditor’s Independence Declaration
To the Directors of BTC Health Limited
In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the audit
of BTC Health Limited for the year ended 30 June 2022, I declare that, to the best of my knowledge and belief,
there have been:
a no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the
audit; and
b no contraventions of any applicable code of professional conduct in relation to the audit.
Grant Thornton Audit Pty Ltd
Chartered Accountants
M A Cunningham
Partner – Audit & Assurance
Melbourne, 16 August 2022
www.grantthornton.com.au
ACN-130 913 594
Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389.
‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or
refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL).
GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member
firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one
another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127
556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards
Legislation.
w
Independent Auditor’s Report
To the Members of BTC health Limited
Report on the audit of the financial report
Opinion
Grant Thornton Audit Pty Ltd
Level 22 Tower 5
Collins Square
727 Collins Street
Melbourne VIC 3008
GPO Box 4736
Melbourne VIC 3001
T +61 3 8320 2222
We have audited the financial report of BTC health Limited (the Company), which comprises the statement
of financial position as at 30 June 2022, the statement of profit or loss and other comprehensive income,
statement of changes in equity and statement of cash flows for the year then ended, and notes to the
financial statements, including a summary of significant accounting policies, and the Directors’ declaration.
In our opinion, the accompanying financial report of the Company is in accordance with the Corporations Act
2001, including:
a Giving a true and fair view of the Company’s financial position as at 30 June 2022 and of its performance
for the year ended on that date; and
b Complying with Australian Accounting Standards and the Corporations Regulations 2001.
Basis for opinion
We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those
standards are further described in the Auditor’s Responsibilities for the Audit of the Financial Report section
of our report. We are independent of the Company in accordance with the auditor independence
requirements of the Corporations Act 2001 and the ethical requirements of the Accounting Professional and
Ethical Standards Board’s APES 110 Code of Ethics for Professional Accountants (including Independence
Standards) (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled
our other ethical responsibilities in accordance with the Code.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our
opinion.
Key audit matters
Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of
the financial report of the current period. These matters were addressed in the context of our audit of the financial
report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these
matters.
www.grantthornton.com.au
ACN-130 913 594
Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389.
‘Grant Thornton’ refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or
refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL).
GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member
firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one
another’s acts or omissions. In the Australian context only, the use of the term ‘Grant Thornton’ may refer to Grant Thornton Australia Limited ABN 41 127
556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards
Legislation.
Key audit matter
How our audit addressed the key audit matter
Other financial assets (Note 1j, Note 6, Note 18)
As at 30 June 2022, the Company’s investment
portfolio consisted of two unlisted companies carried at
a fair value of $10,819,890.
These investments are classified as ‘Level 3’ financial
assets under Australian Accounting Standards, which
are defined as having significant unobservable inputs
which make their valuation complex.
This area is a key audit matter due to the quantum of
the financial assets and the significant estimation
involved in determining the value of Level 3 financial
assets.
Our procedures included, amongst others:
• Obtaining a detailed understanding of the underlying
processes for valuing the financial assets through
discussion with individuals across the organisation
and reviewing the relevant documentation;
• Assessing the design and implementation of
relevant controls concerning estimating the fair
value of the financial assets at the year-end date;
• Assessing and challenging management’s valuation
methodology and key assumptions applied, utilising
an auditor’s expert to support this work;
• Evaluating the actual financial performance of each
of the investments by:
− Comparing actual financial and operational
results to management forecasts;
− Performing analytical procedures to identify
unusual trends or movements;
− Holding discussions with management and
reviewing supporting documentation surrounding
business performance and future business
plans;
− Considering whether the forecasts are
appropriate and consistent with the strategies of
the business; and
− Assessing whether the disclosures in the
financial statements, including critical
judgements and estimates, are appropriate.
Information other than the financial report and auditor’s report thereon
The Directors are responsible for the other information. The other information comprises the information included
in the Company’s report for the year ended 30 June 2022 but does not include the financial report and our
auditor’s report thereon.
Our opinion on the financial report does not cover the other information and we do not express any form of
assurance conclusion thereon.
In connection with our audit of the financial report, our responsibility is to read the other information and, in doing
so, consider whether the other information is materially inconsistent with the financial report or our knowledge
obtained in the audit or otherwise appears to be materially misstated.
If, based on the work we have performed, we conclude that there is a material misstatement of this other
information, we are required to report that fact. We have nothing to report in this regard.
Grant Thornton Australia Limited
Responsibilities of the Directors’ for the financial report
The Directors of the Company are responsible for the preparation of the financial report that gives a true and fair
view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal
control as the Directors determine is necessary to enable the preparation of the financial report that gives a true
and fair view and is free from material misstatement, whether due to fraud or error.
In preparing the financial report, the Directors are responsible for assessing the Company’s/Group’s ability to
continue as a going concern, disclosing, as applicable, matters related to going concern and using the going
concern basis of accounting unless the Directors either intend to liquidate the Company/Group or to cease
operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the financial report
Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from
material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance
with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements
can arise from fraud or error and are considered material if, individually or in the aggregate, they could
reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.
A further description of our responsibilities for the audit of the financial report is located at the Auditing and
Assurance Standards Board website at: http://www.auasb.gov.au/auditors_responsibilities/ar1_2020.pdf.This
description forms part of our auditor’s report.
Report on the remuneration report
Opinion on the remuneration report
We have audited the Remuneration Report included in pages 6 to 9 of the Directors’ report for the year
ended 30 June 2022.
In our opinion, the Remuneration Report of BTC health Limited, for the year ended 30 June 2022 complies
with section 300A of the Corporations Act 2001.
Responsibilities
The Directors of the Company are responsible for the preparation and presentation of the Remuneration Report
in accordance with section 300A of the Corporations Act 2001. Our responsibility is to express an opinion on the
Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.
Grant Thornton Audit Pty Ltd
Chartered Accountants
M A Cunningham
Partner – Audit & Assurance
16 August 2022
Grant Thornton Australia Limited
Shareholder Information
As at 8 August 2022
Spread of equity security holdings
Size of Holding
1 – 1,000
1,001 – 5,000
5,001 – 10,000
10,001 – 100,000
100,001 and over
Total
Ordinary
Shareholders
35
294
241
442
140
1,152
Unlisted
Option holders
-
-
-
-
2
2
Substantial holders
Notices under Section 671B of the Corporations Act, disclosing a relevant interest in the company’s shares, have
been received from the following substantial holders as at the date of this report:
Name
NAOS ASSET MANAGEMENT LIMITED
SIGMA COMPANY LIMITED
RICHARD AND KAREN TREAGUS
LHC CAPITAL PARTNERS PTY LTD
COPIA
Equity security holders
Number of shares/votes
Voting power
87,150,504
28,627,553
24,613,207
22,319,290
14,435,715
30.92%
10.16%
8.73%
7.92%
5.12%
The names of the twenty largest holders of quoted equity securities are listed below:
Rank Name
A/C designation
1
2
3
4
5
6
7
8
9
NATIONAL NOMINEES LIMITED
MRS KAREN ELIZABETH TREAGUS
UBS NOMINEES PTY LTD
SIGMA COMPANY LIMITED
BNP PARIBAS NOMS PTY LTD
MR THOMAS CHRISTOPHER FENNELL
SIGMA COMPANY LIMITED
MR CAMPBELL DINWOODIE TAYLOR
MRS SUSAN MAREE WHITING
10 WINDARRI INVESTMENTS PTY LTD
11
12
13
SIGMA COMPANY LIMITED
NAMARONG INVESTMENTS PTY LTD
PRITDOWN PTY LTD
14
LINWIERIK INVESTMENTS PTY LTD
ABEILLE INVESTMENTS PTY LIMITED
15
16 MR NICHOLAS DERMOTT MCDONALD
HANSEN INVESTMENT
Ordinary Shares
held
94,287,400
24,613,207
22,600,000
16,856,467
10,168,276
8,682,787
8,143,533
7,199,751
5,300,000
4,213,727
3,627,553
3,125,000
2,903,419
2,600,000
2,393,771
1,894,239
Voting
Percentage
33.45
8.73
8.02
5.98
3.61
3.08
2.89
2.55
1.88
1.50
1.29
1.11
1.03
0.92
0.85
0.67
BTC HEALTH | ANNUAL REPORT
PG 43
Rank Name
A/C designation
17
BNP PARIBAS NOMINEES PTY LTD
HUB24 CUSTODIAL SERV LTD
GRAY LANE HOLDINGS PTY LTD
18
19 MR ROBERT BEAUMONT FROST
20 MR NIRMAL GREWAL
Ordinary Shares
held
Voting
Percentage
1,817,476
1,327,804
1,187,500
1,100,000
0.64
0.47
0.42
0.39
224,041,910
79.49
Less than marketable parcel holders
The number of holders holding less than a marketable parcel based on the market price was 481.
Voting rights
The voting rights attaching to each class of equity securities are set out below:
Ordinary shares
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a
poll each share shall have one vote.
Options
There are no voting rights attached to unlisted options until they are exercised.
BTC HEALTH | ANNUAL REPORT
PG 44
Corporate
Directory
Registered Office
BTC health Limited
Level 1, 10 Oxley Road
HAWTHORN VIC 3122
Principal Contacts
Richard Treagus Chairman
T +61 417 520 509
rtreagus@btchealth.com.au
Sharon Papworth Company Secretary
T+ 61 402 229 758
spapworth@btchealth.com.au
Link Market Services Limited Tower 4, 727 Collins Street
MELBOURNE VIC 3008
Locked Bag A14
SYDNEY SOUTH NSW 1235 T 1300 554 474
F 02 9287 0303
Auditors
Grant Thornton
Collins Square, Tower 5, 727 Collins Street
MELBOURNE VIC 3008